Zansecimab (LY-3127804) is an immunoglobulin G4-kappa, a monoclonal antibody against angiopoietin 2 (Ang 2). Zansecimab has potential applications in angiogenesis and immune regulation.
References:
[1]. Yen CC, et al. Safety of ramucirumab treatment in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein. Expert Opin Drug Saf. 2022 Feb;21(2):157-166.
[2]. Wang Y, et al. Angiogenesis as a potential treatment strategy for rheumatoid arthritis. Eur J Pharmacol. 2021 Nov 5;910:174500.